Masked Delivery of Allergen in Nanoparticles Safely Attenuates Anaphylactic Response in Murine Models of Peanut Allergy.
Th2
antigen-specific therapy
food allergy
nanoparticle
tolerance
Journal
Frontiers in allergy
ISSN: 2673-6101
Titre abrégé: Front Allergy
Pays: Switzerland
ID NLM: 9918227355906676
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
12
2021
accepted:
12
01
2022
entrez:
7
4
2022
pubmed:
8
4
2022
medline:
8
4
2022
Statut:
epublish
Résumé
Food allergy is a growing health concern worldwide. Current allergen-specific immunotherapy (AIT) approaches require frequent dosing over extended periods of time and may induce anaphylaxis due to allergen-effector cell interactions. A critical need remains to develop novel approaches that refine AIT for the treatment of food allergies. Previous studies show that poly(lactide-co-glycolide) (PLG) nanoscale particles (NP) effectively suppress Th1- and Th17-driven immune pathologies. However, their ability to suppress the distinct Th2-polarized immune responses driving food allergy are unknown. Herein, we describe the safety and efficacy of NPs containing encapsulated peanut allergen in desensitizing murine models of peanut allergy. Peanut extract encapsulation allowed for the safe intravenous delivery of allergen relative to non-encapsulated approaches. Application of 2-3 doses, without the need for dose escalation, was sufficient to achieve prophylactic and therapeutic efficacy, which correlated with suppression of Th2-mediated disease and reduced mast cell degranulation. Efficacy was associated with strong reductions in a broad panel of Th1, Th2, and Th17 cytokines. These results demonstrate the ability of PLG NPs to suppress allergen-specific immune responses to induce a more tolerogenic phenotype, conferring protection from intragastric allergen challenge. These promising studies represent a step forward in the development of improved immunotherapies for food allergy.
Identifiants
pubmed: 35386645
doi: 10.3389/falgy.2022.829605
pmc: PMC8974743
doi:
Types de publication
Journal Article
Langues
eng
Pagination
829605Subventions
Organisme : NIAID NIH HHS
ID : R01 AI155678
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM007863
Pays : United States
Informations de copyright
Copyright © 2022 Hughes, Saunders, Landers, Janczak, Turkistani, Rad, Miller, Podojil, Shea and O'Konek.
Déclaration de conflit d'intérêts
LS, JP, and SM have financial interests in COUR Pharmaceuticals Development Co. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
JAMA Netw Open. 2019 Jan 4;2(1):e185630
pubmed: 30646188
Bioconjug Chem. 2018 Mar 21;29(3):813-823
pubmed: 29148731
Trends Immunol. 2015 Jul;36(7):419-27
pubmed: 26088391
J Allergy Clin Immunol. 2011 Mar;127(3):701-21.e1-70
pubmed: 21377040
Gastroenterology. 2020 May;158(6):1667-1681.e12
pubmed: 32032584
J Allergy Clin Immunol. 2010 Dec;126(6 Suppl):S1-58
pubmed: 21134576
Clin Exp Allergy. 2005 Apr;35(4):408-16
pubmed: 15836747
J Theor Biol. 1994 Jul 7;169(1):23-30
pubmed: 7934072
Int J Pharm. 2017 Oct 30;532(1):229-240
pubmed: 28867450
Adv Drug Deliv Rev. 2017 May 15;114:240-255
pubmed: 28414079
Clin Exp Immunol. 2012 Oct;170(1):18-27
pubmed: 22943197
J Allergy Clin Immunol. 2018 Jun;141(6):2121-2131
pubmed: 29655584
J Allergy Clin Immunol. 2000 Jul;106(1 Pt 1):150-8
pubmed: 10887318
JAMA. 2019 Mar 12;321(10):946-955
pubmed: 30794314
J Allergy Clin Immunol. 2013 Jan;131(1):14-22
pubmed: 23265693
Am J Pathol. 2012 Apr;180(4):1535-46
pubmed: 22322300
Allergy. 2011 Jun;66(6):792-7
pubmed: 21332502
J Allergy Clin Immunol. 2019 Oct;144(4):1058-1073.e3
pubmed: 31175877
Gastroenterology. 2021 Jul;161(1):66-80.e8
pubmed: 33722583
Lancet. 2019 Oct 19;394(10207):1437-1449
pubmed: 31522849
Pediatrics. 2020 Jan;145(1):
pubmed: 31796504
Biotechniques. 2014 Jul 01;57(1):39-44
pubmed: 25005692
Immunity. 2015 Oct 20;43(4):788-802
pubmed: 26410628
J Allergy Clin Immunol. 2020 Apr;145(4):1240-1253.e3
pubmed: 31866435
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
J Exp Med. 2008 Apr 14;205(4):897-913
pubmed: 18378796
World Allergy Organ J. 2015 May 14;8(1):17
pubmed: 26023323
Nanomedicine. 2019 Jun;18:282-291
pubmed: 30352312
Eur J Immunol. 2018 May;48(5):751-756
pubmed: 29427438
J Am Diet Assoc. 2011 Jan;111(1):17-27
pubmed: 21185960
Front Immunol. 2017 Nov 24;8:1604
pubmed: 29225598
J Allergy Clin Immunol. 2001 Aug;108(2 Suppl):S65-71
pubmed: 11498675
Med Sci Monit. 2009 Jun;15(6):CS105-11
pubmed: 19488019
J Microencapsul. 2007 Mar;24(2):117-28
pubmed: 17454423
Immunotargets Ther. 2021 Jan 27;10:1-8
pubmed: 33537245
J Allergy Clin Immunol. 2018 Feb;141(2):491-498
pubmed: 29288078
Biomaterials. 2021 Feb;269:120666
pubmed: 33461057
J Transl Med. 2020 Aug 5;18(1):302
pubmed: 32758254
J Immunol. 2004 May 1;172(9):5405-14
pubmed: 15100281
Allergy. 2020 Jun;75(6):1337-1346
pubmed: 32034781
N Engl J Med. 2018 Nov 22;379(21):1991-2001
pubmed: 30449234
Biomaterials. 2019 Nov;222:119432
pubmed: 31480002
Nat Biotechnol. 2012 Dec;30(12):1217-24
pubmed: 23159881
J Immunol. 2013 Dec 1;191(11):5341-6
pubmed: 24244028
Clin Transl Allergy. 2012 Jan 05;2(1):2
pubmed: 22409879
Trends Immunol. 2013 Aug;34(8):390-7
pubmed: 23648309
Mol Ther. 2017 Jul 5;25(7):1655-1664
pubmed: 28479234
Part Fibre Toxicol. 2012 Nov 09;9:41
pubmed: 23140310
J Allergy Clin Immunol Pract. 2017 Mar - Apr;5(2):250-272
pubmed: 28283151
Crit Rev Immunol. 2013;33(5):389-414
pubmed: 24099300
N Engl J Med. 2012 Jul 19;367(3):233-43
pubmed: 22808958